Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: Real time quantification of minimal residual disease. A pilot study

Leukemia

Volumn 15, Issue 11, 2001, Pages 1696-1700

  Visani, G ^a   Buonamici, S ^b   Malagola, M ^b   Isidori, A ^b   Piccaluga, P P ^b   Martinelli, G ^b   Ottaviani, E ^b   Grafone, T ^b   Baccarani, M ^b   Tura, S ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Chemotherapy; Minimal residual disease; Molecular remission; Qualitative RT PCR; Quantitative RT PCR

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; RETINOIC ACID RECEPTOR; TIOGUANINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ANALYSIS; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHROMOSOME 15; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; GENE FUSION; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PILOT STUDY; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TOXICITY;

EID: 0035158509     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402266     Document Type: Article

References (26)

1. The t(15;17) of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
2. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
3. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor, PML
4. The acute promyelocytic leukemia-specific PML-RAR-alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
5. All trans retinoid acid and in vitro cytokine production by acute promyelocytic leukemia cells
6. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic
7. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA
8. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
9. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
10. Detection of specific polymerase chain reaction product by utilizing the 5′ → 3′ exonuclease activity of Thermus aquaticus DNA polymerase
11. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)
12. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
13. All trans retinoic acid significantly reduces the incidence of early hemorrhagic deaths during induction therapy of acute promyelocytic leukemia
14. Terminal differentiation of promyelocytic leukemia cells in primary cultures in response to retinoic acid
15. Acute promyelocytic leukemia: From genetics to treatment
16. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Clinical results
17. Retinoic acid receptor alpha (RAR-α)region mutations in the PML-RARα fusion gene of acute promyelocytic leukemia (APL) patients after relapse from all-trans retinoic acid (ATRA) therapy
18. Prognostic significance of minimal residual disease detection and PML-RARα isoform type: Long term follow-up in acute promyelocytic leukemia (APL)
19. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
20. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
21. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
22. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study
23. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript
24. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for minimal residual disease
25. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
26. European standardization and quality control program of real time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease detection in leukemia patients